title: Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
abstract: As previously reported, 1007 patients with chronic atrial fibrillation participated in the Copenhagen AFASAK study. Before inclusion to trial, they all had a physical examination, chest roentgenogram, and echocardiogram with determination of left atrial size. This study evaluated the importance of cardiovascular risk factors for development of thromboembolic complications. To exclude any treatment effects on occurrence of thromboembolic complications, we included only the 336 patients from the placebo group. Using Cox's regression model, previous myocardial infarction was a significant risk factor for development of thromboembolic complications. Age, gender, heart failure, chest pain, hypertensive heart disease, diabetes, systolic and diastolic blood pressure, smoking, relative heart volume, and left atrial size were all without statistical importance.
authors.affiliation: Department of Neurology, University Hospital, Copenhagen, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Petersen
authors.forename: J
authors.initials: J
authors.lastname: Kastrup
authors.forename: S
authors.initials: S
authors.lastname: Helweg-Larsen
authors.forename: G
authors.initials: G
authors.lastname: Boysen
authors.forename: J
authors.initials: J
authors.lastname: Godtfredsen
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D003718:Denmark / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D012307:Risk Factors; D015996:Survival Rate; D013923:Thromboembolism / Q000453:epidemiology* / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D014859:Warfarin; D001241:Aspirin